Answers are grounded in this paper and cite their sources.
Optimal management of intermediate-risk prostate cancer remains challenging as it encompasses a heterogeneous spectrum of disease with variability in tumor biology and outcomes.1 Current National Comprehensive Cancer Network (NCCN) guidelines further divide patients into favorable and unfavorable subgroups, in part based on the proportion of positive biopsy cores. Leonard et al2 investigated whether Grade Group (GG) 1 core positivity is associated with adverse pathology at radical prostatectomy. Using a single-center cohort of 307 men, they demonstrated that inclusion of GG1 cores did not improve predictive accuracy of adverse pathology. Authors proposed an alternative stratification approach incorporating MRI-visible GG3 disease and summed tumor length of GG2-GG3 lesions, as an alternative measure of tumor volume, which improved prediction of adverse pathology. We commend the authors for their invaluable addition to the literature. Despite these promising results, limitations remain to be addressed in future studies. The primary outcome may not have been uniformly assessed, as patients with < 50% GG1 core positivity and PSA of 10 to 20 ng/dL on traditional NCCN criteria would have been excluded by authors' modified criteria, and lymph node dissection was performed at the discretion of individual surgeons rather than systematically, potentially underestimating adverse pathology. Furthermore, the novel tumor volume metric excluded systematic biopsy cores, focusing only on MRI-targeted regions of interest. This approach could further underestimate true disease burden in patients whose highest grade disease was found outside MRI-visible lesions. Nevertheless, the study supports a more biology-driven risk stratification model yet; a small cohort (10% of patients) was reclassified into a more favorable risk stratum, aligning with efforts to reduce overtreatment in indolent malignancy. These encouraging findings merit external validation in larger multicenter cohorts. Future research should include patients on active surveillance, extend pathologic outcomes to include margin status, and extend follow-up to evaluate long-term endpoints including biochemical recurrence and metastasis.
No takes yet. Share an insight, caveat, or question.
Abedi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: